GSK Plc: Jemperli Trial Shows Unprecedented Results

(RTTNews) - GSK plc (GSK, GSK.L) reported longer-term results from the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center evaluating Jemperli or dostarlimab as a first-line treatment-as an alternative to surgery-for mismatch repair deficient locally advanced rectal cancer. The trial showed 100% clinical complete response rate in 42 patients who completed treatment with dostarlimab.

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: "We look forward to evaluating dostarlimab in certain colorectal cancers in our ongoing AZUR-1 and AZUR-2 registrational studies."

For More Such Health News, visit

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.